Choolip & Sciences츌립앤사이언스
291650 · KOSDAQ · ₩291650 · 츌립앤사이언스
- Market cap
- ₩73B
- Enterprise value
- ₩69B
- P/E
- —
- P/B
- 1.7×
- Dividend yield
- 0.0%
- ROE
- −27.6%
- Net margin
- −215.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−40.3% from the high
₩1,350Today: ₩2,325 – ₩2,610₩3,996
Returns
- 1W−7.6%
- 1M+29.3%
- 3M+25.5%
- 6M−30.1%
- YTD+57.3%
- 1Y+12.8%
- Volume today
- 66,791
- 1.0× the 20-day average
- Traded today
- ₩163M
- Listed shares
- 30,519,621
- EPS (12 months)
- −₩382
- Earnings yield −16.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat35.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Choolip & Sciences stock overview
Choolip & Sciences (츌립앤사이언스, KRX: 291650) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech firm developing innovative cancer therapies based on its Aptamer Technology Platform and ApDC drug-conjugate platform, targeting solid and blood cancers. Its shares closed at ₩2,385 on Oct 27, 2026, down 0.63% on the day, giving it a market value of ₩73B.
Key facts
- Market cap
- ₩73B
- Sector
- Biotech & Pharma
- Latest price change
- −0.63%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean biotech firm developing innovative cancer therapies based on its Aptamer Technology Platform and ApDC drug-conjugate platform, targeting solid and blood cancers.
Quick answers about Choolip & Sciences
- What does Choolip & Sciences do?
- The company is a Korean biotech firm developing innovative cancer therapies based on its Aptamer Technology Platform and ApDC drug-conjugate platform, targeting solid and blood cancers. It was spun off from POSTECH in 2011 and has expanded into aptamer oligonucleotide synthesis and aptamer discovery services, a bioanalytical CRO business for pharmaceutical and biotech clients (covering ADCs, peptides, and oligonucleotide drugs), a lung cancer risk test, and consumer goods distribution through home shopping channels. Its lead drug candidate AST-201 is in a Phase 1 trial in Korea.
- What is the market cap of Choolip & Sciences?
- The market capitalisation of Choolip & Sciences was ₩73B at the close on Oct 27, 2026.
- Who are the largest shareholders of Choolip & Sciences?
- According to the latest official filings, the largest reported holders are Altcast (22.48%, as of Aug 20, 2026); Wellnew&Co. (19.66%, as of Aug 20, 2026); Daehyeon Gigen (10.79%, as of Aug 20, 2026).
- When is the next earnings report from Choolip & Sciences?
- Korean companies rarely announce results dates in advance. Based on when Choolip & Sciences filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean biotech firm developing innovative cancer therapies based on its Aptamer Technology Platform and ApDC drug-conjugate platform, targeting solid and blood cancers. It was spun off from POSTECH in 2011 and has expanded into aptamer oligonucleotide synthesis and aptamer discovery services, a bioanalytical CRO business for pharmaceutical and biotech clients (covering ADCs, peptides, and oligonucleotide drugs), a lung cancer risk test, and consumer goods distribution through home shopping channels. Its lead drug candidate AST-201 is in a Phase 1 trial in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 츌립앤사이언스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 정집훈
- Founded
- Apr 2011
- Listed
- Sep 2020
- Listed shares
- 30,519,621
- Fiscal year ends
- Month 12
- Website
- www.aptsci.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- 5%+ holding reportAug 20, 2026
- Insider shareholding reportAug 20, 2026
- 5%+ holding reportAug 20, 2026
- Insider shareholding reportAug 20, 2026
- Insider shareholding reportAug 20, 2026
Titles in Korean until English translations are added.
Also known as: Choolip & Sciences / 츌립앤사이언스 / 291650 / KRX:291650
Source: KRX statistical information